Restructuring Costs

9 Months Ended

Sep. 30, 2017

Restructuring and Related Activities [Abstract]

Restructuring Costs

10. Restructuring Costs

In June 2016, the Company halted investment in its former lead product candidate PNT2258 and closed the related Phase 2 clinical trials to further enrollment. As a result, the Company closed its research facility in Plymouth, Michigan, renegotiated and terminated certain contracts, and implemented staff reductions in the United States and Canada.

The following table summarizes restructuring activities for the three months ended September 30, 2017:

	Contract Termination			Employee Termination			Total
	(in thousands)
Accrual balance at June 30, 2017	$	204		$	2		$	206
Adjustments to research and development expense		(38	)		—			(38	)
Cash payments		(56	)		(2	)		(58	)
Accrual balance at September 30, 2017	$	110		$	—		$	110

The following table summarizes restructuring activities for the nine months ended September 30, 2017:

	Contract Termination			Employee Termination			Total
	(in thousands)
Accrual balance at December 31, 2016	$	664		$	99		$	763
Adjustments to research and development expense		(112	)		—			(112	)
Cash payments		(442	)		(99	)		(541	)
Accrual balance at September 30, 2017	$	110		$	—		$	110

Adjustments to research and development expense represent revisions to estimated costs to close the PNT2258 Phase 2 clinical trials. The accrual balance is currently expected to be substantially paid by the end of 2017.